ORAMED PHARMACEUTICALS INC. Proceeds from Common Stock Issued
ORAMED PHARMACEUTICALS INC. (ORMP) reported Proceeds from Common Stock Issued of $2.43 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2025-03-27
- ORAMED PHARMACEUTICALS INC. proceeds from issuance of common stock for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- ORAMED PHARMACEUTICALS INC. proceeds from issuance of common stock for the quarter ending 2023-09-30 was -$2.00K, a 100.05% decline year-over-year.
- ORAMED PHARMACEUTICALS INC. proceeds from issuance of common stock for the quarter ending 2023-06-30 was $0.00.
- ORAMED PHARMACEUTICALS INC. proceeds from issuance of common stock for the quarter ending 2023-03-31 was $2.43M, a 77.11% decline year-over-year.
- ORAMED PHARMACEUTICALS INC. proceeds from issuance of common stock for fiscal 2023 was $2.43M, a 78.89% decline from fiscal 2022.
- ORAMED PHARMACEUTICALS INC. proceeds from issuance of common stock for fiscal 2022 was $11.50M.
- ORAMED PHARMACEUTICALS INC. proceeds from issuance of common stock for fiscal 2021 was $10.62M.
- ORAMED PHARMACEUTICALS INC. proceeds from issuance of common stock for fiscal 2018 was $21.66M, a 86528.00% increase from fiscal 2017.
| Period end | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 4 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 6 month as first filed | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 9 month as first filed | Proceeds from Issuance of Common Stock 12 month | Proceeds from Issuance of Common Stock 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$2.00K derived: sum of 2 quarters · filed 2025-03-27 | -$2.00K derived: sum of 3 quarters · filed 2025-03-27 | $2.43M 10-K · filed 2025-03-27 | ||||
| 2023-09-30 | -$2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$2.00K derived: sum of 2 quarters · filed 2024-11-07 | $2.43M 10-Q · filed 2024-11-07 | $6.58M derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $2.43M 10-Q · filed 2024-08-14 | $6.58M derived: sum of 3 quarters · filed 2024-08-14 | $10.96M derived: sum of 4 quarters · filed 2024-08-14 | ||||
| 2023-03-31 | $2.43M 10-Q · filed 2024-05-09 | $6.58M derived: sum of 2 quarters · filed 2024-05-09 | $10.96M derived: sum of 3 quarters · filed 2024-05-09 | $3.31M derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | $4.16M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $8.53M derived: sum of 2 quarters · filed 2024-03-06 | $883.00K derived: sum of 3 quarters · filed 2024-03-06 | $11.50M 10-K · filed 2024-03-06 | $10.62M 10-K · filed 2023-03-06 | |||
| 2022-09-30 | $4.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$3.27M derived: sum of 2 quarters · filed 2023-11-09 | $7.34M 10-Q · filed 2023-11-09 | $10.62M 10-Q · filed 2022-11-10 | ||||
| 2022-06-30 | -$7.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $2.97M 10-Q · filed 2023-08-10 | $10.62M 10-Q · filed 2022-08-10 | |||||
| 2022-03-31 | $10.62M 10-Q · filed 2022-05-12 | |||||||
| 2021-12-31 | $10.62M 10-QT · filed 2022-03-30 | |||||||
| 2021-11-30 | $10.62M 10-Q · filed 2022-01-11 | |||||||
| 2021-08-31 | $10.62M 10-K · filed 2021-11-24 | |||||||
| 2020-05-31 | $19.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-07-07 | $22.29M derived: sum of 2 quarters · filed 2020-07-07 | $22.30M 10-Q · filed 2020-07-07 | |||||
| 2020-02-29 | $2.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-04-06 | $2.32M 10-Q · filed 2020-04-06 | ||||||
| 2019-11-30 | $1.00K 10-Q · filed 2020-01-09 | |||||||
| 2018-08-31 | $16.49M derived: 10-K 12 month − 10-Q 9 month · filed 2018-11-28 | $16.78M derived: sum of 2 quarters · filed 2019-07-10 | $17.43M derived: sum of 3 quarters · filed 2019-07-10 | $21.66M 10-K · filed 2018-11-28 | ||||
| 2018-05-31 | $283.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-07-10 | $934.00K derived: sum of 2 quarters · filed 2019-07-10 | $5.16M 10-Q · filed 2019-07-10 | |||||
| 2018-02-28 | $651.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-04-10 | $4.88M 10-Q · filed 2019-04-10 | ||||||
| 2017-11-30 | $4.23M 10-Q · filed 2019-01-14 | |||||||
| 2017-08-31 | $25.00K 10-K · filed 2018-11-28 | |||||||
| 2016-08-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-11-28 | $0.00 derived: sum of 2 quarters · filed 2018-11-28 | $10.59M 10-K · filed 2018-11-28 | |||||
| 2016-05-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-07-06 | $10.59M 10-Q · filed 2017-07-06 | ||||||
| 2016-02-29 | $10.59M 10-Q · filed 2017-04-05 | |||||||
| 2015-08-31 | $4.88M derived: 10-K 12 month − 10-Q 9 month · filed 2017-11-29 | $4.88M derived: sum of 2 quarters · filed 2017-11-29 | $4.88M derived: sum of 3 quarters · filed 2017-11-29 | $9.71M 10-K · filed 2017-11-29 | ||||
| 2015-05-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-07-06 | $0.00 derived: sum of 2 quarters · filed 2016-07-06 | $4.83M 10-Q · filed 2016-07-06 | $4.83M derived: sum of 4 quarters · filed 2016-11-25 | ||||
| 2015-02-28 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-04-06 | $4.83M 10-Q · filed 2016-04-06 | $4.83M derived: sum of 3 quarters · filed 2016-11-25 | $4.83M derived: sum of 4 quarters · filed 2016-11-25 | ||||
| 2014-11-30 | $4.83M 10-Q · filed 2016-01-13 | $4.83M derived: sum of 2 quarters · filed 2016-11-25 | $4.83M derived: sum of 3 quarters · filed 2016-11-25 | |||||
| 2014-08-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-11-25 | $0.00 derived: sum of 2 quarters · filed 2016-11-25 | $14.89M 10-K · filed 2016-11-25 | |||||
| 2014-05-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-07-01 | $14.89M 10-Q · filed 2015-07-01 | $14.89M 10-Q · filed 2014-07-14 | |||||
| 2014-02-28 | $14.89M 10-Q · filed 2015-04-03 | $14.89M 10-Q · filed 2014-04-10 | ||||||
| 2013-08-31 | $5.71M 10-K · filed 2015-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |